Integrating Pharma R&D and Supply Chain Issues with Commerical Strategy

Bridgehead is pleased to announce that David Alderson has joined its UK team as Principal Consultant. David has pharmaceutical marketing, commercial and supply chain experience, gained over 17 years in both the Pharma and Biotech sectors.  Much of his career has focused on integrating research, development and supply chain issues with commercial strategy.  He has experience of a broad range of therapy areas, including pain, respiratory, inflammation, and infectious diseases.

Previously David was with Napp Pharmaceutical Group, where he was Marketing Group Brand Manager. Prior to that he was Strategic Marketing Manager at Cambridge Antibody Technology (CAT), covering strategy, evaluation, portfolio management and alliances.  Before joining CAT he was Respiratory & Dermatology Business Franchise Manager for Novartis Pharma AG, based in Basel.

David started his pharmaceutical career in Glaxo, initially in manufacturing, establishing the non-CFC metered dose inhaler production facility at Speke and then moving to Canada as Engineering Manager with GlaxoWellcome. He then moved to the Global Manufacturing HQ as Respiratory Manufacturing Strategy Manager, where he was involved in the GW and SB merger integration planning. His final role in GSK was as Business & Commercial Analysis Manager in the Respiratory TA.

David has a MBA from Cranfield, is a Member of the Chartered Institute of Marketing, and is a Chartered Engineer with a MEng degree from Southampton University.

Bridgehead’s CEO, Timothy Fitzgerald commented “David joins us at an exciting time that has seen year on year revenues growth by of over 60%, despite the challenging environment within the biotechnology sector”. “I feel certain that his broad commercial experience within both the biotechnology and pharmaceutical sectors will be of great value to Bridgehead and our clients”.   

About Bridgehead

Bridgehead International is a leading biopharmaceutical consultancy group, offering a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain.  Our mission is to work with commercial organisations, government agencies and the investment community to ensure that:

  • Life science organisations have the funding, structure and strategic focus to deliver high levels of innovation and financial return
  • Patients have rapid and broad access to new innovative medicines, medical devices and diagnostic tools, particularly in areas of high unmet need.

With over 40 consultants and 60 associates in Europe, North America and Asia, Bridgehead provides a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modelling and intellectual property skills and experience.

Bridgehead is globally recognised for its expertise in:

  • Technical and commercial evaluation
  • Due diligence and Experts’ Reports
  • Forecasting and valuation
  • Market access
  • Pricing and reimbursement strategy
  • Health economics and health technology assessment. 

In 2007, Bridgehead was honoured with The Queen’s Award for Enterprise, in the International Trade section, for outstanding achievement in international trade. The Queen’s Award for Enterprise is the highest honour that can be bestowed upon a UK company and is the UK’s top award for business performance.

In 2009, Bridgehead was voted UK Strategic Advisor of the Year – Healthcare, in the ACQ Finance Magazine’s Global Awards.

 

20th October 2009.